Zachary Hornby
Chief Executive Officer at BOUNDLESS BIO, INC.
Net worth: 3 M $ as of 2024-04-29
Profile
Zachary D.
Hornby is currently the President, Chief Executive Officer & Director at Boundless Bio, Inc. He is also a Director at Novome Biotechnologies, Inc. Additionally, he holds director positions at Independa, Inc., Radionetics Oncology, Inc., and Aardvark Therapeutics, Inc. He previously served as the Chief Operating Officer at Ignyta Operating, Inc. and held the position of Operating Partner at City Hill Ventures LLC.
Prior to his current roles, he was the Senior Director-Business Development at Fate Therapeutics, Inc. and the Director-Business Development at Halozyme Therapeutics, Inc. He also served as the Chief Operating Officer at Ignyta, Inc. and held the position of Business Development Associate at Shire Pharmaceuticals, Inc. Before that, he worked as the Senior Manager-Products at Neurocrine Biosciences, Inc. He has a background in life sciences consulting at The Lek.
Mr. Hornby completed his undergraduate and graduate degrees at Stanford University and obtained an MBA from Harvard Business School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
BOUNDLESS BIO INC.
1.15% | 2024-03-27 | 256,410 ( 1.15% ) | 3 M $ | 2024-04-29 |
Zachary Hornby active positions
| Companies | Position | Start |
|---|---|---|
| BOUNDLESS BIO, INC. | Chief Executive Officer | 2019-05-18 |
Ignyta Operating, Inc.
 Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Ignyta Operating, Inc. develops molecular diagnostics for cancer and immunology. It is a biotechnology company developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. The firm's products include TrailblazeDx for RA, TrailblazeTx for RA, TrailblazeDx for SLE, TrailblazePx for SLE and TrailblazeTx for SLE. The company was founded in August 2011 by Jonathan E. Lim and Gary S. Firestein and is headquartered in San Diego, CA. | Chief Operating Officer | 2012-07-31 |
Independa, Inc.
 Independa, Inc. Packaged SoftwareTechnology Services Independa, Inc. provides software-based solution. It allows caregivers and family members to video chat, send Facebook messages and photos, set up appointments and medication reminders, and play games with their older loved ones. The firm also offers blood-pressure monitoring devices, scales and glucometers, and can serve as a door sensor and emergency-alert system. The company was founded by Kian Saneii in 2009 and is headquartered in San Diego, CA. | Director/Board Member | - |
Aardvark Therapeutics, Inc.
 Aardvark Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA. | Private Equity Investor | - |
City Hill Ventures LLC
 City Hill Ventures LLC Investment ManagersFinance City Hill Ventures LLC (City Hill Ventures) is a venture capital firm founded in 2010 by Jonathan Lim. The firm is headquartered in San Diego, California. | Private Equity Investor | - |
Novome Biotechnologies, Inc.
 Novome Biotechnologies, Inc. BiotechnologyHealth Technology Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA. | Director/Board Member | 2021-05-25 |
Radionetics Oncology, Inc.
 Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Director/Board Member | - |
Former positions of Zachary Hornby
| Companies | Position | End |
|---|---|---|
| IGNYTA INC | Chief Operating Officer | 2018-06-30 |
| IGNYTA INC | Director of Finance/CFO | 2014-05-29 |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Zachary Hornby
| Stanford University | Graduate Degree |
| Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| BOUNDLESS BIO, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Shire Pharmaceuticals, Inc.
 Shire Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shire Pharmaceuticals, Inc. manufactures pharmaceutical products. The company offers solutions for attention deficit & hyperactivity disorder, human genetic therapies, gastrointestinal, and renal diseases. The company was founded in 1986 and is headquartered in Wayne, PA | Health Technology |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Ignyta Operating, Inc. develops molecular diagnostics for cancer and immunology. It is a biotechnology company developing personalized medicines for high unmet need cancer indications, based on cancer genome mining and sequencing. The firm's products include TrailblazeDx for RA, TrailblazeTx for RA, TrailblazeDx for SLE, TrailblazePx for SLE and TrailblazeTx for SLE. The company was founded in August 2011 by Jonathan E. Lim and Gary S. Firestein and is headquartered in San Diego, CA. | Health Technology |
The Lek/Alcar Consulting Group, Inc.
 The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Independa, Inc.
Independa, Inc. Packaged SoftwareTechnology Services Independa, Inc. provides software-based solution. It allows caregivers and family members to video chat, send Facebook messages and photos, set up appointments and medication reminders, and play games with their older loved ones. The firm also offers blood-pressure monitoring devices, scales and glucometers, and can serve as a door sensor and emergency-alert system. The company was founded by Kian Saneii in 2009 and is headquartered in San Diego, CA. | Technology Services |
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA. | Health Technology |
City Hill Ventures LLC
City Hill Ventures LLC Investment ManagersFinance City Hill Ventures LLC (City Hill Ventures) is a venture capital firm founded in 2010 by Jonathan Lim. The firm is headquartered in San Diego, California. | Finance |
Novome Biotechnologies, Inc.
Novome Biotechnologies, Inc. BiotechnologyHealth Technology Novome Biotechnologies, Inc. operates as a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The company was founded by William DeLoache, Weston Whitaker, Liz Shepherd and Zachary Russ in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
Radionetics Oncology, Inc.
Radionetics Oncology, Inc. Pharmaceuticals: MajorHealth Technology Radionetics Oncology, Inc. is a clinical stage radiopharmaceutical company based in Menlo Park, CA. Radionetics Oncology, Inc. focuses on the discovery and development of novel radiotherapeutics for the treatment of various oncology indications. Radionetics Oncology spun out of Crinetics Pharmaceuticals and is supported by Frazier Life Sciences, 5AM Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Investments. The company is advancing a pipeline of small molecule radioligands that target G-protein coupled receptors to treat a wide range of cancers, including adrenocortical carcinoma, breast cancer, and lung cancer. The company's platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes selectively to tumors expressing peptide receptors. The company's pipeline consists of multiple lead drug candidates, and they are conducting additional drug discovery efforts in collaboration with Crinetics Pharmaceuticals. The market for radiopharmaceuticals is expected to rise to $12.6 billion by 2027. The company was founded by Scott R. Struthers, and Paul A. Grayson has been the CEO since 2024. | Health Technology |
- Stock Market
- Insiders
- Zachary Hornby
